Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

GIMOTI™, Novel Nasal Spray Developed for Treatment of Gastroparesisin Adults

GIMOTI™ (metoclopramide), novel nasal spray developed by Evoke Pharma, Inc specifically for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

Diabetic gastroparesis refers to GI disorder affecting millions of patients worldwide.With the current treatments available in the market patients claim that there is no sufficient relief for their gastroparesis symptoms. This unique non-oral treatment optionhelps patients to relieve symptoms and help improve their quality of life.

Most common symptoms of patients suffering from gastroparesis are nausea, abdominal pain, bloating, early satiety as well as vomiting which can be severe and debilitating.GIMOTI is administered nasally, bypassing the diseased GI track, allowing the drug to enter the bloodstream directly and therefore providing predictable delivery of the therapy.

US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for GIMOTI™ (metoclopramide) nasal spray, the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024